文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

心率变异性联合临床与实验室指标预测脓毒症患者病情恶化

Heart Rate Variability, Clinical and Laboratory Measures to Predict Future Deterioration in Patients Presenting With Sepsis.
PubMed 文献 · Shock · 2019-01-01
一句话结论联合心率变异性与实验室指标的模型可区分脓毒症患者恶化风险:高风险组恶化率35%,低风险组2%。

研究纳入急诊科1247例符合1992年共识会议脓毒症标准且能签署知情同意的21岁及以上患者,记录就诊1小时内的临床、实验室及心率变异性(HRV)数据,随访72小时内的病情恶化。832例数据完整者中68例(8%)达到至少一个终点。联合实验室值与HRV指标的模型预测性能最佳,AUROC为0.80(95%CI 0.65-0.92),优于单独临床指标(AUROC=0.69,95%CI 0.54-0.83)、单独实验室指标(AUROC=0.77,95%CI 0.63-0.90)和单独HRV指标(AUROC=0.76,95%CI 0.61-0.90)。HRV+LAB模型识别出高风险组(占全部患者14%)恶化风险为4.3倍(95%CI 3.2-5.4),恶化发生率35%;低风险组(占61%)风险为0.2倍(95%CI 0.1-0.4),恶化发生率2%。作者认为该模型可能有助于急诊医生评估脓毒症患者的恶化风险,值得验证和进一步评估。

要点

  • 联合HRV与实验室指标的模型预测脓毒症恶化的AUROC为0.80(95%CI 0.65-0.92),优于单独临床、实验室或HRV指标。
  • HRV+LAB模型识别的高风险组(占14%)恶化风险为4.3倍(95%CI 3.2-5.4),恶化发生率35%。
  • 低风险组(占61%)恶化风险为0.2倍(95%CI 0.1-0.4),恶化发生率2%。
  • 研究纳入符合1992年共识会议脓毒症标准的急诊成人患者,于就诊1小时内采集数据,随访72小时。
  • 作者认为该模型可能帮助急诊医生评估恶化风险,但尚需验证和进一步评估。

适用人群与场景

  • 急诊科21岁及以上患者,符合1992年共识会议脓毒症标准,且能直接或通过代理人签署知情同意。

诊断标准与关键阈值

  • 脓毒症诊断采用1992年共识会议标准。
  • 恶化终点为72小时内达到至少一个终点(原文未具体列出终点定义)。

研究设计与关键结果

  • 研究类型为预测模型推导与性能评估,纳入1247例急诊脓毒症患者,832例数据完整,其中68例(8%)达到至少一个终点。
  • 联合实验室值与HRV指标的模型AUROC为0.80(95%CI 0.65-0.92),优于单独临床指标(AUROC=0.69,95%CI 0.54-0.83)、单独实验室指标(AUROC=0.77,95%CI 0.63-0.90)和单独HRV指标(AUROC=0.76,95%CI 0.61-0.90)。
  • HRV+LAB模型识别的高风险组占全部患者的14%,恶化风险为4.3倍(95%CI 3.2-5.4),恶化发生率为35%。
  • HRV+LAB模型识别的低风险组占全部患者的61%,恶化风险为0.2倍(95%CI 0.1-0.4),恶化发生率为2%。

证据类型、等级与局限

  • 证据类型:预测模型推导与性能评估研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为联合HRV与实验室指标的模型可能帮助急诊医生评估脓毒症患者的恶化风险,但需验证和进一步评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Risk stratification of patients presenting to the emergency department (ED) with sepsis can be challenging. We derived and evaluated performance of a predictive model containing clinical, laboratory, and heart rate variability (HRV) measures to quantify risk of deterioration in this population.

METHODS: ED patients aged 21 and older satisfying the 1992 consensus conference criteria for sepsis and able to consent (directly or through a surrogate) were enrolled (n = 1,247). Patients had clinical, laboratory, and HRV data recorded within 1 h of ED presentation, and were followed to identify deterioration within 72 h.

RESULTS: Eight hundred thirty-two patients had complete data, of whom 68 (8%) reached at least one endpoint. Optimal predictive performance was derived from a combination of laboratory values and HRV metrics with an area under the receiver-operating curve (AUROC) of 0.80 (95% CI, 0.65-0.92). This combination of variables was superior to clinical (AUROC = 0.69, 95% CI, 0.54-0.83), laboratory (AUROC = 0.77, 95% CI, 0.63-0.90), and HRV measures (AUROC = 0.76, 95% CI, 0.61-0.90) alone. The HRV+LAB model identified a high-risk cohort of patients (14% of all patients) with a 4.3-fold (95% CI, 3.2-5.4) increased risk of deterioration (incidence of deterioration: 35%), as well as a low-risk group (61% of all patients) with 0.2-fold (95% CI 0.1-0.4) risk of deterioration (incidence of deterioration: 2%).

CONCLUSIONS: A model that combines HRV and laboratory values may help ED physicians evaluate risk of deterioration in patients with sepsis and merits validation and further evaluation.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Barnaby DP, Fernando SM, Herry CL, et al. Heart Rate Variability, Clinical and Laboratory Measures to Predict Future Deterioration in Patients Presenting With Sepsis. Shock. 2019. PMID: 29847498. doi:10.1097/SHK.0000000000001192

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。